| About AndroBioSys Inc. | ||||||||
 |
||||||||
|
||||||||
|
AndroBioSys, Inc. (ABS), is a biotechnology company dedicated to the development of novel treatments for prostate disease. Based on technologies developed at Roswell Park Cancer Institute (website), AndroBioSys is pioneering new approaches to make treatment of prostate cancer curative, not palliative. Preventing progression of prostate disease is intertwined intimately with disruption of the androgen axis. ABS performs contract research screening services for academic, biotechnology and pharmaceutical clients and develops collaborative partnerships to discover new drugs to proprietary prostate disease targets. The success of the company will be fueled by the following societal and pharmaceutical industry trends: Outsourcing – another trend in the pharma industry is to outsource research and in-license promising compounds to decrease overall costs related to developing therapeutic products. Partnerships – the trend in the pharma and biotech industry is to develop partnerships or seek acquisitions to help fill the diminishing product pipeline. High Attrition Rate of Therapeutics – the high cost of drug development requires better, more predictive models for testing therapeutics to reduce the failure rate at the expensive later stages of clinical trials. Only 1 in 20 oncology drugs that enter clinical trials reach the market. Unmet medical need – current treatments for prostate disease are less than optimal (none are curative) and there is high potential for related medical uses of developed compounds and assays. Shifting Demographics – as the “Baby Boomer” population continues to age, the size of the target group affected by prostate disease and cancer continues to increase. The 2007 US male population over 50 is estimated at 41 million. Relative Affluence – this target population has more expendable income than previous generations and expects better medical care with fewer side effects and higher quality of life. |
||||||||
|
||||||||
